Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.
ICES, Toronto, Ontario, Canada.
J Am Geriatr Soc. 2023 Oct;71(10):3099-3109. doi: 10.1111/jgs.18477. Epub 2023 Jun 20.
Emerging evidence shows loneliness is associated with polypharmacy and high-risk medications in older adults. Despite notable sex-based differences in the prevalence in each of loneliness and polypharmacy, the role of sex in the relationship between loneliness and polypharmacy is unclear. We explored the relationship between loneliness and polypharmacy in older female and male respondents and described sex-related variations in prescribed medication subclasses.
We performed a cross-sectional analysis of representative data from the Canadian Community Health Survey-Healthy Aging cycle (2008/2009) linked to health administrative databases in Ontario respondents aged 66 years and older. Loneliness was measured using the Three-Item Loneliness Scale, with respondents classified as not lonely, moderately lonely, or severely lonely. Polypharmacy was defined as five or more concurrently-prescribed medications. Sex-stratified multivariable logistic regression models with survey weights were used to assess the relationship between loneliness and polypharmacy. Among those with polypharmacy, we examined the distribution of prescribed medication subclasses and potentially inappropriate medications.
Of the 2348 individuals included in this study, 54.6% were female respondents. The prevalence of polypharmacy was highest in those with severe loneliness both in female (no loneliness, 32.4%; moderate loneliness, 36.5%; severe loneliness, 44.1%) and male respondents (32.5%, 32.2%, and 42.5%). Severe loneliness was significantly associated with greater adjusted odds of polypharmacy in female respondents (OR = 1.59; 95% CI: 1.01-2.50) but this association was attenuated after adjustment in male respondents (OR = 1.00; 95% CI: 0.56-1.80). Among those with polypharmacy, antidepressants were more commonly prescribed in female respondents with severe loneliness (38.7% [95% CI: 27.3-50.0]) compared to those who were moderately lonely (17.7% [95% CI: 9.3-26.2]).
Severe loneliness was independently associated with polypharmacy in older female but not male respondents. Clinicians should consider loneliness as an important risk factor in medication reviews and deprescribing efforts to minimize medication-related harms, particularly in older women.
新出现的证据表明,孤独感与老年人的多种药物治疗和高危药物有关。尽管孤独感和多种药物治疗在患病率方面存在显著的性别差异,但孤独感与多种药物治疗之间的关系中性别所起的作用尚不清楚。我们探讨了孤独感与老年女性和男性受访者之间的多种药物治疗之间的关系,并描述了处方药子类别的性别相关差异。
我们对安大略省年龄在 66 岁及以上的代表性数据进行了横断面分析,这些数据来自加拿大社区健康调查-健康老龄化周期(2008/2009 年),并与健康管理数据库相关联。使用三项目孤独量表衡量孤独感,将受访者分为不孤独、中度孤独和重度孤独。多种药物治疗定义为同时服用五种或更多种药物。使用带有调查权重的性别分层多变量逻辑回归模型评估孤独感与多种药物治疗之间的关系。在那些服用多种药物的患者中,我们检查了处方药子类别的分布和潜在的不适当药物。
在这项研究中,共有 2348 名患者,其中 54.6%为女性受访者。在女性(无孤独感、中度孤独感和重度孤独感分别为 32.4%、36.5%和 44.1%)和男性(32.5%、32.2%和 42.5%)受访者中,严重孤独感患者的多种药物治疗患病率最高。在女性受访者中,严重孤独感与更高的调整后多种药物治疗的比值比显著相关(OR=1.59;95%CI:1.01-2.50),但在男性受访者中,这种关联在调整后减弱(OR=1.00;95%CI:0.56-1.80)。在服用多种药物的患者中,与中度孤独感的患者相比,严重孤独感的女性患者更常开抗抑郁药(38.7%[95%CI:27.3-50.0])。
严重孤独感与老年女性但不是男性受访者的多种药物治疗独立相关。临床医生应将孤独感视为药物审查和减少药物治疗的重要危险因素,以最大限度地减少药物相关危害,特别是在老年女性中。